Your browser doesn't support javascript.
loading
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
Kraus, Bettina J; Weir, Matthew R; Bakris, George L; Mattheus, Michaela; Cherney, David Z I; Sattar, Naveed; Heerspink, Hiddo J L; Ritter, Ivana; von Eynatten, Maximilian; Zinman, Bernard; Inzucchi, Silvio E; Wanner, Christoph; Koitka-Weber, Audrey.
Affiliation
  • Kraus BJ; Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany. Electronic address: bk@doktorkraus.de.
  • Weir MR; Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Bakris GL; Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, Chicago, Illinois, USA.
  • Mattheus M; Biostatistics, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany.
  • Cherney DZI; Department of Medicine and Department of Physiology, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Sattar N; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands; The George Institute for Global Health, Sydney, New South Wales, Australia; University of New South Wales, Sydney, New South Wales, Australia.
  • Ritter I; Pharmacovigilance, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • von Eynatten M; Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
  • Zinman B; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.
  • Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut, USA.
  • Wanner C; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
  • Koitka-Weber A; Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Kidney Int ; 99(3): 750-762, 2021 03.
Article in En | MEDLINE | ID: mdl-33181154
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Kidney Int Year: 2021 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Kidney Int Year: 2021 Type: Article